New therapeutic approaches for Hodgkin lymphoma

At the 20th Congress of the European Hematology Association (EHA), Andrew Davies, BSc (Hons), BM (Hons), MRCP, PhD, of the University of Southampton, Southampton, UK, discusses clinical trials of new treatments for Hodgkin lymphoma (HL). Topics of interest include bendamustine-containing regimen (BeGEV) as induction chemotherapy prior to autologous stem cell transplantation for patients with relapsed or refractory HL and the phase 1 trial of doxorubicin, vinblastine, dacarbazine, and lenalidomide (AVD-Rev) for elderly patients with HL.

Year of Production:
Running Time:


Comments are closed.